Furthermore, a recent study by Satoh et al. revealed that RIP2 mRNA is more highly expressed in non-T cell peripheral blood mononuclear cells (PBMC) from MS patients compared to healthy controls [19] suggesting that the NOD2 and NOD1 pathways are inherently more active in MS patients. This evidence concerns the gene NOD1 and myeloid sarcoma.